Pure Global
NCT06211829

An Evaluation of a Antimicrobial Stewardship Recommendation Bundle for Staphylococcus Aureus Bloodstream Infections

Methodist Health System·ClinicalTrials.govRecruitment Completed
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Bacterial Infections
Study type
Observational
Sponsor & location
Primary sponsor
Methodist Health System
Location
Dallas, United States of America
Timeline & enrollment
Phase
N/A
Start date
May 18, 2022
End date
May 18, 2024
Enrollment
208 participants
Primary outcome

number of Staphylococcus Aureus blood stream infections (SAB)

Summary

In July 2020, a bundle (Appendix C) was implemented at Methodist Dallas Medical Center where
 all patients with SAB were reviewed by the antimicrobial stewardship pharmacist (Monday -
 Friday from 0700 to 1500), a note outlining optimal interventions was written in the
 electronic medical record (EMR), and the recommendations were communicated to the primary
 team via secure messaging or telephone

ICD-10 classifications
Bacterial infection, unspecifiedBacterial, viral and other infectious agentsOther bacterial intestinal infectionsOther bacterial diseasesOther specified bacterial intestinal infections
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06211829
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06211829 through Pure Global AI's free database. This phase not specified trial is sponsored by Methodist Health System and is currently Recruitment Completed. The study focuses on Bacterial Infections. Target enrollment is 208 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.